Molecular Biomedicine Lab
Stem Cell l Cell therapy l Drug screening
Molecular Biomedicine Lab (MBL) is a global stem cell research group that has a network with Max Planck Institute, the world-leading research institute. MBL aims to develop novel stem cell technologies to treat incurable disease. Direct conversion is a technology that can generate target cells from skin cells by bypassing the pluripotent stage thereby solving the tumorigenic risk of pluripotent stem cells. MBL focuses on developing stem cell treatments that repair damaged tissues or damaged organs using patient-specific stem cells generated by direct conversion technology, organoid technology or stem cell-based tissues produced by 3D bio-printing technology.
Curriculum Vitae
– 2009 ~ 2016 : Assistant Professor
– 2017 ~ Present : Associate Professor
– 2010 ~ Present : Director, Hans Schöler Stem Cell Research Center (HSSCRC)
– 2012 ~ 2016 : Group leader, Max Planck Partner Group-MBL
– 2017 ~ Present : CEO, SuPine Therapeutics
Academic Credential
– 1993 ~ 2001 : B.S., Biology, Dongguk University, Korea
– 2001 ~ 2004 : M.S., Medical Science, Yonsei University College of Medicine, Korea
– 2005 ~ 2009 : Ph.D., Biology, Max Planck Institute for Molecular Biomedicine, Germany
Awards/Honors/Memberships
– 2008 International Society of Stem cell Research (ISSCR), Junior Investigator Award, USA
– 2009 MTZ-MPI Award (MTZ foundation, Germany)
– 2010 Otto-Hahn Award (Max Planck Society, Germany)
– 2010, 2011 “The leaders of Korea after 10 years”, Dong-A Newspaper
– 2013 Hanrim Leading Scientist, KAST
– 2017 Young Korean Academy of Science and Technology (Y-KAST), KAST
– 2017 Award of Minister of Small and Medium Business Administration, Korea
– 2018 Award of HYUNDAI Heavy Industries, HYUNDAI
